Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2

Terminated

• Conditions: Malignant Peripheral Nerve Sheath Tumors
• Interventions: Drug: imatinib mesylate

• Registration Number: NCT00427583
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors

Detailed Description

Not available

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2007-01-25
• Study First Submitted QC: 2007-01-26
• Study First Posted: 2007-01-29
• Primary Completion: 2009-04
• Status Verified: 2012-08
• Last Update Submitted: 2012-08-06
• Last Update Posted: 2012-08-07

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
STI571	imatinib mesylate	-

Primary Outcome Measures

Name	Time	Method
Response rate assessed by a Tumor MRI scan every 6 weeks or if clinically indicated.	Every 36 weeks

Secondary Outcome Measures

Name	Time	Method
Time to progression assessed by an MRI scan.	Every 36 weeks
Overall survival	Every 36 weeks
Safety and tolerability assessed by abnormal lab values (hematology, biochemistry, urinalysis), by physical examination and vital signs	Every 36 weeks

Trial Locations

Locations (1)

Novartis Investigative Site; 🇩🇪 Hamburg, Germany